Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulmonx Corporation - Common Stock (NQ: LUNG )

7.050 +0.290 (+4.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pulmonx Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
From Pulmonx Corporation
Via Business Wire
Pulmonx to Present at Upcoming September Investor Conferences
From Pulmonx Corporation
Via Business Wire
Where Pulmonx Stands With Analysts
Within the last quarter, Pulmonx (NASDAQ:LUNG) has observed the following analyst ratings: 
Via Benzinga
Pulmonx: Q2 Earnings Insights
Pulmonx (NASDAQ:LUNG) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Pulmonx beat estimated earnings by... 
Via Benzinga
Earnings Preview: Pulmonx
Pulmonx (NASDAQ:LUNG) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Pulmonx will report... 
Via Benzinga
Recap: Pulmonx Q4 Earnings
Pulmonx (NASDAQ:LUNG) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Pulmonx... 
Via Benzinga
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Pulmonx Corporation
Via Business Wire
Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
From Pulmonx Corporation
Via Business Wire
Pulmonx: Q1 Earnings Insights
Pulmonx (NASDAQ:LUNG) reported its Q1 earnings results on Tuesday, May 3, 2022 at 05:05 PM. Here's what investors need to know about the announcement. Earnings Pulmonx missed estimated earnings by... 
Via Benzinga
Where Pulmonx Stands With Analysts
Within the last quarter, Pulmonx (NASDAQ:LUNG) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1... 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on Wednesday. Camber Energy, Inc. (NYSE: CEI) rose 45.2% to $0.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades 
Via Benzinga
Global Stocks, Futures Crash; Nasdaq In Bear Market, Oil Soars Above $105 On Russia Attack
U.S. stock index futures crashed along with global markets on Thursday as Russia’s assault on Ukraine sent investors fleeing risky assets, while the tech-heavy Nasdaq was set to open in a bear market. 
Via Talk Markets
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
55 Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company. 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
Pulmonx Corporation (LUNG) Q3 2021 Earnings Call Transcript
LUNG earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale
Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment
From Pulmonx Corporation
Via Business Wire
3 Healthcare Stocks That Might Skyrocket When COVID Is Over
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over? 
Via The Motley Fool
Exposures COVID-19
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
From Pulmonx Corporation
Via Business Wire
Return on Capital Employed Overview: Pulmonx
After pulling data from Benzinga Pro it seems like during Q2, Pulmonx (NASDAQ:LUNG) brought in sales totaling $12.20 million. However, earnings decreased 0.58%, resulting in a... 
Via Benzinga
Pulmonx Corporation (LUNG) Q2 2021 Earnings Call Transcript
LUNG earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.